References
- Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:1649-72.
- Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-8. doi:10.1056/NEJM199811053391901. PMID:9801394.
- Davey JC, Bodwell JE, Gosse JA, Hamilton JW. Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci. 2007;98:75-86. doi:10.1093/toxsci/kfm013. PMID:17283378.
- Sheldon LA. Inhibition of E2F1 Activity and Cell Cycle Progression by Arsenic via Retinoblastoma Protein. Cell Cycle. 2017; in press.
- Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11-20. doi:10.1038/nrm714. PMID:11823794.
- Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013;14:297-306. doi:10.1038/nrm3567. PMID:23594950.
- Kolupaeva V, Janssens V. PP1 and PP2A phosphatases–cooperating partners in modulating retinoblastoma protein activation. FEBS J. 2013;280:627-43. doi:10.1111/j.1742-4658.2012.08511.x. PMID:22299668.